Zebrafish heart failure models for the evaluation of chemical probes and drugs

Assay and Drug Development Technologies

Volumn 11, Issue 9-10, 2013, Pages 561-572

  Huang, Cheng Chen ^a   Monte, Aaron ^b   Cook, James M ^c   Kabir, Mohd Shahjahan ^c,d   Peterson, Karl P ^a  

^a UNIVERSITY OF WISCONSIN RIVER FALLS   (United States)

^b UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A11; ARISTOLOCHIC ACID; ATRIAL NATRIURETIC FACTOR; C25; CHALCONE DERIVATIVE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHENOL DERIVATIVE; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL EMBRYO; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; EMBRYO; FEMALE; FOLLOW UP; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; ZEBRA FISH;

ANIMALS; BIOLOGICAL ASSAY; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HUMANS; TREATMENT OUTCOME; ZEBRAFISH;

EID: 84890936239     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.548     Document Type: Article

References (44)

1. The American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220.
2. McMurray J, Pfeffer M: Heart failure. Lancet 2005;365:1877-1889.
3. Feenstra J, Grobbee D, Remme W, Stricker B: Drug-induced heart failure. J Am Coll Cardiol 1999;33:1152-1162.
4. Gharib M, Burnett K: Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002;4:235-242.
5. Anker S, von Haehling S: Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-470.
6. MERIT-HF Investigators: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:9-13.
7. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congested heart failure. N Engl J Med 1991;325:293-302.
8. Ko D, Hebert P, Coffey C, et al.: Adverse effects of b-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004;164:1389-1394.
9. Zafrir B, Amir O: Beta blocker therapy, decompensated heart failure, and inotropic interactios: current perspectives. Isr Med Assoc J 2012;14:184-189.
10. Cohn J, Tognoni G: Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
11. Follath F, Cleland J, Just H, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196-202.
12. Delgado R, Nawar M, Zewail A, et al.: Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 2004;109:1428-1433.
13. Simunek T, Klimtova I, Kaplanova J, et al.: Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 2004;6:377-387.
14. Dixon J, Spinale F: Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009;1:262-271.
15. Braunwald E: Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
16. Zon L, Peterson R: In vivo drug discovery in the zebrafish. Nat Rev Drug Dis 2005;4:35-44.
17. Huang C, Chen P, Huang C, Yu J: Aristolochic acid induces heart failure in zebrafish embryos that is mediated by inflammation. Toxicol Sci 2007;100:486-494.
18. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/ cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-59.
19. Ferreira A, Matsubara L, Matsubara B: Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008;6:278-281.
20. van Acker S, Kramer K, Voest E, et al.: Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother Pharmacol 1996;38:95-101.
21. Ding Y, Sun X, Huang W, et al.: Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circ Res 2011;109:658-669.
22. Westerfield M: The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio). University of Oregon Press, Eugene, OR, 2000.
23. Hsiao C, Tsai W, Horng L, Tsai H: Molecular structure and developmental expression of three muscle-type troponin T genes in zebrafish. Dev Dyn 2003;227:266-279.
24. Gerlag P, van Meijel J: High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988;148:286-291.
25. Pitt B, Zannad F, Remme W, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
26. Cokkinos D, Haralabopoulos G, Kostis J, Toutouzas P, HELAS Investigators: Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8:428-432.
27. von Haehling S, Jankowska E, Morgenthaler N, et al.: Comparison of midregional proatrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-1980.
28. Mueller C, Scholer A, Laule-Kilian K, et al.: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-654.
29. Hudson M, O'Connor C, Gattis W, et al.: Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004;147:546-552.
30. Favata, M, Horiuchi K, Manos E, et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
31. Bueno O, Molkentin J: Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002;91:776-781.
32. Lorenz K, Schmitt J, Schmitteckert E, Lohse M: A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009;15:75-83.
33. Craig E, Stevens M, Vaillancourt R, Camenisch T: MAP3Ks as central regulators of cell fate during development. Dev Dyn 2008;237:3102-3114.
34. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem J: Identification of aristolochic acid in Chinese herbs. Lancet 1994;343:174.
35. Vanherweghem J, Depierreux M, Tielemans C, et al.: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-391.
36. Denvir M, Tucker C, Mullins J: Systolic and diastolic ventricular function in zebrafish embryos: influence of norepinephrine, MS-222 and temperature. BMC Biotechnol 2008;8:21.
37. Iwanaga Y, Miyazaki S: Heart failure, chronic kidney disease, and biomarker. Circ J 2010;74:1274-1282.
38. Drummond I, Majumdar A, Hentschel H, et al.: Early development of the zebrafish pronephros and analysis of mutations affecting pronephric function. Development 1998;125:4655-4667.
39. Ding Y, Chen Y: Developmental netphtrotoxicity of aristolochic acid in a zebrafish model. Toxicol Appl Pharmacol 2012;261:50-65.
40. Huang C, Tu C, Hsiao D, Hsieh F, Tsai H: Germ-line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish. Dev Dyn 2003;228:30-40.
41. Lawson N, Weinstein B: In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307-318.
42. Perner B, Englert C, Bollig F: The Wilms tumor genes wt1a and wt1b control different steps during formation of the zebrafish pronephros. Dev Biol 2006:309;87-96.
43. Renshaw S, Loynes C, Trushell D, Elworthy S, Ingham P, Whyte M: A transgenic zebrafish model of neutrophilic inflammation. Blood 2006;108:3976-3978.
44. Krzysciak W: Activity of selected aromatic amino acids in biological systems. Acta Biochim Pol 2011;58:461-466.